Circulating Dipeptidyl Peptidase 3 levels, an Antagonist of Angiotensin-(1–7), in Acute Heart Failure: Insights from the PUSH-AHF trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Levels of Circulating Dipeptidyl Peptidase 3, an Inhibitor of Angiotensin-(1–7), in Acute Heart Failure: Findings from the PUSH-AHF Study

  • By

  • Stijn Legtenberg

  • Karine Santos

  • Iris E. Beldhuis

  • Oliver Hartmann

  • Lara E.E.C. Zonneveld

  • Peter van der Meer

  • Jan A. Krikken

  • Wybe Nieuwland

  • Dirk J. van Veldhuisen

  • Adriaan A. Voors

  • Kevin Damman

  • Jozine M. ter Maaten

  • September 4, 2026

Share

  • 1

    A biomarker substudy of PUSH-AHF examined circulating dipeptidyl peptidase 3 (cDPP3) and its associations with clinical characteristics, decongestive response, and outcomes in acute heart failure.

  • 2

    Higher baseline cDPP3 was associated with lower 24-hour natriuresis under standard care. This association was not observed with natriuresis-guided diuretic therapy, although the treatment-by-cDPP3 interaction was not significant.

  • 3

    PUSH-AHF enrolled 310 adults with new-onset or decompensated acute heart failure. This substudy included 287 patients with available baseline cDPP3 measurements.

  • 4

    Plasma cDPP3 was measured using a luminometric immunoassay at baseline, 24, 48, and 72 hours, and discharge. Measurement availability varied across time points.

  • 5

    Dual primary endpoints were 24-hour natriuresis and time to first all-cause death or heart failure hospitalization within 180 days. cDPP3 did not significantly modify treatment effects on the 180-day combined endpoint.

Original Source(s)

Circulating Dipeptidyl Peptidase 3 levels, an Antagonist of Angiotensin-(1–7), in Acute Heart Failure: Insights from the PUSH-AHF trial

  • by Stijn Legtenberg, Karine Santos, Iris E. Beldhuis, Oliver Hartmann, Lara E.E.C. Zonneveld, Peter van der Meer, Jan A. Krikken, Wybe Nieuwland, Dirk J. van Veldhuisen, Adriaan A. Voors, Kevin Damman, Jozine M. ter Maaten

  • September 4, 2026

Related Content

Medical Oddities: Could multilingualism keep you young?

From multilingual minds to pomegranate hearts, gastric mischief, and swishable tea, science stays delightfully odd.

Seasonal variation and extreme cold exposure in heart failure with mildly reduced ejection fraction

A National Survey of Compensation and Productivity in Advanced Heart Failure and Transplant Cardiology